Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares for the month of November 2025. The filing details a share repurchase executed on November 4, 2025, pursuant to a non-discretionary agreement with BNP Paribas SA, announced on September 30, 2025.
Key Financial Metrics and Transaction Details
The filing focuses exclusively on capital structure changes via share buybacks and does not report operational financial metrics such as revenue, profit, cash flow, or debt levels.
- Shares Purchased (Nov 4, 2025): 175,000 ordinary shares.
- Price Range: Lowest 1,747.00p; Highest 1,790.00p.
- Volume-Weighted Average Price (VWAP): 1,768.39p.
- Accumulated Buybacks (Since Sept 30, 2025): 7,649,000 ordinary shares.
- Treasury Shares Held: 255,113,844 ordinary shares.
- Shares in Issue (Excluding Treasury): 4,060,309,755 ordinary shares.
- Total Voting Rights: 4,060,309,755.
- Treasury Voting Rights Percentage: 6.28%.
Material Changes Versus Prior Period
The filing does not provide comparative financial data against prior periods. The material change reported is the reduction of shares in issue and the increase in treasury shares following the November 4 transaction. The total number of voting rights remains constant at 4,060,309,755, as treasury shares do not carry voting rights.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in GSK's 2024 Annual Report on Form 20-F and Q3 2025 Results. The transaction was executed across multiple trading venues, including XLON, CHIX, and BATE.
Important Facts for Investor Verification
- Verify the total number of shares in issue (4,060,309,755) to ensure accurate calculation of ownership percentages and voting thresholds under FCA Disclosure Guidance and Transparency Rules.
- Confirm the current percentage of voting rights held in treasury (6.28%) to assess potential dilution or concentration of voting power among remaining shareholders.
- Review the non-discretionary agreement terms announced on September 30, 2025, to understand the remaining capacity and timeline of the current buyback programme.
- Note that this filing does not contain operational financial results; refer to the Q3 2025 Results or Form 20-F for revenue and profit data.